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The management of mycotic aneurysm has always been subject to controversy. The aim of this paper is to review the literature on
the intracranial infected aneurysm from pathogenesis till management while focusing mainly on the endovascular interventions.
This novel solution seems to provide additional benefits and long-term favorable outcomes.
1. Introduction
Intracranial infectious aneurysms (IIAs) or mycotic
aneurysms are a rare entity and represent 0.7 to 5.4%
of all cerebral aneurysms [1]. The name mycotic originated
from the fact of their resemblance to fungal vegetation [2].
Although they can be caused by fungal pathogen, they are
most commonly due to bacterial infection [3]. Historically
the management of mycotic aneurysms relied on surgery and
antibiotics with limited use of endovascular therapy fearing
the risk of overwhelming infection by introducing a foreign
body to an infected region [4]. This theoretical fear exists in
spite of the absence of reports in the literature on persistent
infection or abscesses formation following endovascular
surgery [5]. A recent review of the literature that examined
287 cases of cerebral mycotic aneurysms (CMAs) [5] found
no postprocedural infection in the 46 cases treated by
endovascular coiling. In another study, coiling was successful
even in the presence of active bacteremia [6]. However,
the safety and efficacy of these techniques are published
in case-series and case-reports. Therefore, endovascular
treatment remains an individualized therapy with no
standard guidelines [7]. Given the inconsistency in IIA’s
evolution and response to treatment and given the lack of
randomized controlled trials (RCTs), there has not been any
widely accepted standard management [5]. The purpose of
this paper is to briefly review cerebral mycotic aneurysms
while focusing on the endovascular approach for their
management.
2. Methodology
We performed a literature review using MEDLINE. The fol-
lowing meshwork words were used individually or in combi-
nation: mycotic, cerebral, infectious, intracranial, aneurysm,
endovascular, treatment, management, and Onyx. We man-
aged to find 3 articles on the use of Onyx in the treatment
of IIAs. Other articles were included in our study using a
more extensive search to briefly review the pathogenesis of
the disease and to evaluate other alternative managements.
The search was limited to the studies published in English.
3. Epidemiology
IIAs represent 5% of all intracranial aneurysms [8]. Currently
there are no rigorous population-based epidemiological stud-
ies, but an analysis of a pooled cohort by Ducruet et al.
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Figure 1: Management algorithm.
revealed that 65% of patients with IIA have an underlying
endocarditis [5]. The prevalence has decreased from 86%
after the advent of antibiotic era [9]. The most common
sources of infectious bacteremia remain to be intravenous
(IV) drug abuse and poor dental hygiene. Direct invasion
of the vascular wall from a nearby infectious focus, such as
cavernous sinus thrombophlebitis and bacterial meningitis,
is also common cause of IAA. The median age tend to vary
depending on the reviews between 35.1 [5] and 53 years [10].
Some studies reported a higher male predominance while
the pooled cohort done by Ducruet et al. showed similar
proportions of both genders (52% males and 48% females)
[5].
4. Pathology and Pathogenesis
The process is the result of a developing infectious process
involving the arterial wall [11]. The acute inflammation leads
to neutrophils infiltration followed by degradation of the
media and adventitia, fragmentation of the internal elastic
lamina and proliferation of the intima. The weakened vessel
wall in combination with the pulsatile pressure in the vas-
culature leads to an aneurysm formation and consequential
growth [5]. Most of the authors prefer the term pseudoa-
neurysm [12], although both are widely used.Many processes
may contribute to the development of IIAs: septic emboli
lodging at distal branches, spreading infection involving
BioMed Research International 3
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Figure 2: A patient with a history of intravenous drug abuse was admitted to an outside hospital for treatment of endocarditis. MRI at
this time demonstrated multiple cerebral septic emboli and mycotic aneurysms (a–c). Two weeks after initiation of antibiotics, the patient
had a significant headache and CT scan demonstrated new hemorrhage in the superior parietal lobe (d). The patient was transferred to our
hospital for further care, andCTAandMRI at this time demonstrated 2 persistentmycotic aneurysmswith hemorrhage surrounding the 7mm
aneurysm arising from the distal cortical branch from themiddle cerebral artery (e–h). As the patient required a cardiac valve replacement and
would receive full anticoagulation and had a hemorrhage 2 weeks after initiation of antibiotics, the intervention with the ruptured aneurysm
was considered the best course of therapy. Due to the distal nature of the aneurysm, microsurgical removal was deemed the best therapy
((i), intraoperative image of cortically based aneurysm). Intraoperative angiogram demonstrated complete resection of the cortically based
aneurysm with only the single aneurysm remaining (j, k). Follow CTA demonstrated resolution of the final remaining aneurysm.
the vasa vasorum, and periarterial lymphatic and vascular
manipulation precipitating infection [2], all of which can lead
to focal polymorphic neutrophil infiltration with enzymes
and proinflammatory cytokine secretions. Consequently,
the inflammatory reaction contributes to vessel friability,
weakening, and pseudoaneurysm formation. Grossly, the
aneurysm appears friable, having a thin-wall and wide or
absent neck. This predisposes the aneurysm to rupture and
consequent bleeding. If it ruptures, the mortality rate can be
extreme, as high as 80% [13, 14]. Even though a fusiform
morphology points toward a mycotic pseudoaneurysm, a
saccularmorphology does not exclude it, as it has been shown
that approximately 41% of mycotic aneurysm in the literature
are saccular [5].
Even though virus and fungi can cause IIAs, bacterial
infection remains by far the most predominant cause. The
most commonly reported bacterial pathogens are S. aureus
and Streptococcus species. IIAs have been described following
viral infection such as HIV-1 and VZV [15, 16] and fungal
infection such as Candida and Aspergillus [4]. IIAs can be
formed at distal branching points when the infectious agent
spreads by hematogenous route, as seen in endocarditis, or
it can be formed near the infected foci when the infectious
agent spreads by direct invasion of the arterial wall from the
extravascular site [5, 9]. The latter is more commonly seen
in immunocompromised patients [9, 17]. The most common
location of IIA seems to be the anterior circulation, mainly
the MCA and its distal branches, contributing to as much as
50–78% of all IIAs [4, 5, 9].
5. Clinical Manifestations and Diagnosis
IIA’s natural history is somewhat unpredictable but linked
to significant mortality ranging from 30% to 80% if rupture
occurs [18]. Some studies reported rupture as the most
common presentation of IIAs, and most of the studies
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Table 1: Response of aneurysm to medical treatment.
Disappearance Decrease in size No change in size Increase in size Additional aneurysm development
Bartakke et al. [20] 29% 18.5% 15% 22% 15%
Corr et al. [24] 33% 17% 33% 17%
reported that headache followed by fever is themost common
symptom [18]. However, a recent review found septic infarct
to be more common than intraparenchymal hemorrhage
(IPH) and focal neurologic deficit to be a more common
initial presentation than fever [5]. The bleeding can be sub-
arachnoid, intraparenchymal, or intraventricular [5]. Other
signs and symptoms of IIAs are due to the underlying
etiology [19], such as septic emboli, fever, and chills, or to the
mass effect of the aneurysm. Silent IIAs are not uncommon
and can represent up to 10% of autopsy cases [20]. It is
noteworthy that in contrast to saccular aneurysm, size does
not seem to predict the risk of rupture [21]. When the CMA
is extracranial, the presentation tends to be different. When
this is the case, the most common presentation is a pulsatile
painful lateral cervical mass, which may compress the cranial
nerves resulting in dysphagia and dysphonia [22]. If it is left
untreated, it may rupture causing a hemorrhagic shock or
may deliver septic emboli to the anterior circulation of the
brain [22].
The diagnosis of mycotic aneurysms relies on the pres-
ence of a predisposing infectious process with an aneurysm
documented by vascular imaging. Some pieces of literature
even recommend screening patient with bacterial endocardi-
tis for intracranial aneurysms given the strong correlation
between the two [5]. Digital subtraction angiography (DSA)
continues to be the gold standard for the diagnosis of IIA [20],
although CT angiography and magnetic resonance imaging
can be used [5]. Some of the findings on DSA that points
toward IIA are the fusiform shape, the multiplicity, the distal
location, and the change in size on follow-up angiography [5].
Positive culture from the wall itself can confirm the diagnosis
[5]. Other indicators are positive blood culture (only found in
35.6%), leukocytosis, elevated erythrocyte sedimentation rate
(ESR), and elevated C-reactive protein (CRP) [5].
6. Treatment
6.1. Approach to Management. Given the lack of RCTs,
there are currently no standards to guide clinical decision-
making. Treatment involves antimicrobial agents, surgery,
endovascular approach, and/or a combination of them [9].
As a rule, IIAs management depends essentially on whether
it has ruptured or not [9], the aneurysm characteristics, and
the overall health status of the patient.
For unruptured IIAs in patients with high surgical risk,
conservative treatment with antibiotic is the mainstay ther-
apy. Antibiotics are guided by blood and cerebrospinal fluid
(CSF) cultures. If the results were negative, empiric treat-
ment based on suspected pathogens is continued. A period
of four to six weeks of antimicrobial therapy is generally
recommended [23]. An aneurysm has a high surgical risk if
there is a circumferential vessel involvement, if the location
is proximal, or if parent artery sacrifice cannot be done due
to considerable neurological deficits. These characteristics
render the surgery or the endovascular therapy difficult and
unsafe. Follow-up angiography is necessary to assess the risk
of rupture, which is always present even with appropriate
medical therapy [5]. Conservative management yields differ-
ent outcomes in terms of change in size or disappearance of
the aneurysm. The outcome with conservative management
is worse than that of invasive treatment when the latter is
indicated [20, 24]. Table 1 summarizes some of the outcomes
after conservative management. Resistance to conservative
treatment is suspected when the aneurysm size increases or
remains the same and/or when other aneurysms develop
while the patient is on the appropriate antibiotics. In this
case, invasivemanagement is warranted [1, 9].However, some
authors advise for endovascular or surgical management
whenever the aneurysm is accessible [21], regardless of the
rupture status.
In the case of unruptured aneurysmwithout high surgical
risk, endovascular or surgical treatment is advised irrespec-
tively of the size because of the high risk of rupture and the
weak association between size and rupture [21].
Ruptured aneurysms on the other hand should be imme-
diately secured by surgical or endovascular means. The suc-
cess of endovascular or surgical treatment dependsmostly on
the aneurysm morphology, the comorbidities of the patient,
and the presence of an associated intracerebral hemorrhage
[25]. The choice between endovascular and open surgery is
complex and should be individualized.
6.2. Surgical Management. A good candidate for surgery
would be a young symptomatic patient with surgically
accessible IIA and/or when a significant hematoma with
mass effect is present [9]. Open surgery however would be
challenging when the location of the aneurysm is in the distal
anterior circulation. From a technical point of view, clipping
a mycotic aneurysm is more difficult than a regular saccular
aneurysm due to the friable nature of the aneurysm and the
absence or the deformity of the neck. In addition, localizing
a distal branch aneurysm might be challenging. However,
image guidance technology may help in that issue. Open
surgery faces amajor limitation when the patient is candidate
for cardiothoracic surgery, which requires heparinization
and anticoagulation. This puts the patient at higher risk of
intracranial bleeding after craniotomy. Even more, studies
have shown that cardiothoracic surgery following craniotomy
increases the risk of perioperative heart failure [26–28]. The
major complications of surgery are perioperative rupture
and clip erosion of the parent artery [7, 29]. An alternative
option in an unruptured aneurysm to delay surgery and
give adequate time for the aneurysm to become fibrotic,
minimizing therefore the risk of perioperative rupture and
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Table 2: Characteristics of different agents used in embolization.
Agent Properties Advantages Inconvenience
NBCA (i) Nonabsorbable, adhesive(ii) Rapid polymerization
(i) High durability
(ii) Minimal inflammatory effect
High risk of gluing the
microcatheter (instant
polymerization)
Detachable
coil
(i) New generation soft coil
(ii) Hydrogel coated coils
(increase in volume once
in contact with blood, therefore
decreasing initial coil-packing density)
(i) Durable
(ii) Decreased risk of rupture
(versus old-generation coil)
Risk of rupture
(transient increase in
pressure while deployment)
Onyx Nonabsorbable, adhesive
(i) Slow polymerization
(ii) Multiple injection from
single catheter
(i) Requires familiarity
(ii) Requires special catheter
enabling direct clipping [5]. Even then, the risk of surgery
remains high [5]. For all the previous reasons and given
that many patients with IIA are quite ill and have multiple
comorbidities, surgery is falling out of favor [29]. In these
settings, the endovascular option seems to replace surgery
as standard of care in treatment of IIAs [29], yet the optimal
treatment paradigm remains controversial.
6.3. Endovascular Management. Endovascular techniques
are rapidly gaining ground in the management of all types of
cerebral aneurysms [30–41]. For mycotic lesions, the advan-
tages of endovascular therapy over surgery are a decreased
risk of anesthesia particularly in patients with impaired valve
function, rapid institution of anticoagulation therapy, and
shortening of the delay between aneurysm treatment and
cardiac surgery. The delay can be reduced from 2-3 weeks
to as little as 1 day [5, 9, 25, 27]. A major indication for
endovascular therapy would be a patient with high surgical
risk, a patient candidate for cardiac surgery [5], and a
surgically inaccessible or multiple IIAs [42].
Current strategies in endovascular therapy include an
indirect approach by parent artery occlusion (PAO) using
coils or liquid embolic agents (LEAs) and direct approach
by embolization of the aneurysm using coils, stent-assisted
coiling (SAC), flow diverters, and LEAs [7, 43, 44]. PAO is
attempted when the aneurysm is distally located, dysplastic,
involving the whole circumference of the parent vessel, and
having a complex morphology, provided that the area of the
brain supplied by that artery is noneloquent. Intracranial
balloon test occlusion or amobarbital injection testing can
help determining whether the area is eloquent or not when
the provider is unsure [7]. IIAs that are proximal in location
such as those arising from cavernous ICA tend to be more
treated by a direct approach, while both approaches are
equally used for aneurysms that are distal in location such as
those arising fromMCA and posterior cerebral artery (PCA).
When the aneurysm is difficult to reach, LEAs can be used for
distal PAO (N-butyl 2-cyanoacrylate, NBCA, ethylen-vinyl
alcohol copolymer, Onyx).The advantages and disadvantages
of the different agents used are summarized in Table 2.
Endovascular coiling has been attempted by Andreou
et al. [10] and Chapot et al. [42] with successful occlusion,
without any rupture or death (Table 3) [1, 42, 45]. Sugg et al.
[25] presented a case-report in which an IIA was treated
by Neuroform stent. The major drawback was the use of
antiplatelet agents [27], which can be critical if the aneurysm
ruptured. Jadhav et al. [29] used Onyx 18 to treat 2 cases
of mycotic aneurysm, one due to its resistance to antibiotic
treatment and the other due to its high risk of rupture
in the setting of chronic anticoagulation in a patient with
antiphospholipid syndrome [29]. Onyx has the advantage
over NBCA of being nonadhesive, with a long precipitation
time. This allows for more precise control resulting in more
satisfactory embolization [7, 29].
Katakura et al. treated pediatric IIAs using NBCA and
coils for PAO with no complications from the occlusion
of distal MCA branches [46]. Eddleman et al. approached
pediatric patients with IIAs that presented with rupture
[7]. One patient was treated with PAO using Onyx and
another patient was treated by direct coiling followed by
Onyx embolization due to persistent filling of the aneurysm
on follow-up DSA [7]. The treatment was effective and safe
(Tables 3 and 4). For management algorithm, please refer to
Figure 1.
At our institution, Thomas Jefferson University Hospital,
4 mycotic aneurysms, 3 of which were associated with
arteriovenous malformation and 1 with moyamoya disease,
were successfully treated. Complete aneurysm obliteration
was achieved in all patients by using Onyx 18 to occlude
the aneurysm or to trap the parent vessel, with a procedural
related mortality and morbidity rate of 0%. Unfortunately,
2 of our patients died from cardiac complications caused
by their endocarditis. The technique that seemed to provide
additional safety was the injection just proximal to the
aneurysm, thus limiting the distal migration while the filling
is taking place. There was neither instances of reflux nor
accidental migration of embolic material. There were no
recanalization or rebleeding on followup. We conclude that
parent vessel trapping with Onyx 18 offers a simple, safe, and
effective means of achieving obliteration of distal challenging
aneurysms. Avoiding the need for aneurysm catheterization
reduces intra-arterialmanipulation and thus practically elim-
inates the risk of aneurysm perforation. Figure 2 illustrates a
case of IIA that was treated by Onyx 18.
7. Conclusion
IIAs have a rupture risk of less than 2% [47]. Nevertheless
the mortality rate after rupture could reach as high as
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Table 3: Aneurysm coiling with or without stent.
GDC∗ ± stent Modality of treatment Response
Yen et al. [45] (i) Helistent 3.5 × 9mm + GDC for left cavernous carotid(ii) Helistent 4 × 9mm + GDC for right cavernous carotid
Complete occlusion
No complication
Nakahara et al. [1] (i) 9.2mm PCA, ultrasoft GDC(ii) 5.7 mm distal left ACA, ultrasoft GDC, treated by PAO
Complete occlusion
No complication
Chapot et al. [42]
(18 cases)
(i) Nonselective cyanoacrylate
(ii) Coil embolization
Complete occlusion
No rupture or death
∗GDC: Guglielmi detachable coils.
Table 4: Results from treatment with Onyx.
Onyx Rx Location Treatment/complication
Eddleman et al. [7, 49]: Case 1 M3 4 × 4mm Onyx 18, no complication, no filling
Eddleman et al. [7, 49]: Case 2 MCA anterior division 4 × 6mm
Coiling but persistent filling → Onyx 18
Complications: radiologic distal occlusion due to reflux,
but clinically insignificant.
Zhao et al. [43] (i) 11 × 14mm(ii) P3 of PCA
Onyx 18 under local anesthesia
No complications
la Barge et al. [52] (i) Right parietooccipital artery (fusiform)(ii) Left parietotemporal artery
Onyx 18
No complications
Complete occlusion
Our institution
(i) Left MCA at M2
(ii) Left distal ACA
(iii) 2 other patients
Complete occlusion
0% combined mortality morbidity
80% [21, 48]. In the last decade the flourishing advances in
endovascular techniques expanded the scope of its applica-
tion and have transformed it from a rescue procedure to a
first-line treatment as recommended bymany authors [28, 42,
48–51].Themajority of the patients with IIAs are quite ill with
multiple comorbidities.Therefore, an endovascular approach
would be a more suitable treatment option [29]. Unruptured
IIAs can be treated with antibiotics and follow-up imaging
in 1-2 weeks after therapy. If the aneurysm decreased in size
or resolved, then the patient most likely will not need an
invasive therapy. Continuation of the antimicrobial in that
case would be appropriate while noting that a decrease in size
does not correlate with a decrease in the risk of rupture [4].
If the aneurysm is increasing in size or remaining the same,
invasive procedures become mandatory. The choice between
open surgery and endovascular management depends on a
multitude of factors already described above, but the most
important are the following: the morphology and location of
the aneurysm, whether it is possible or not to sacrifice the
parent artery, whether the patient needs or has received valve
replacement surgery, and lastly the patient overall health
status. Even though there is no head to head RCTs comparing
endovascular and open surgery, most infectious aneurysms
are being treated by endovascular method [7]. The IIAs of
patients considered “strongly immunocompromised” such
as those with AIDS, those on chemotherapy, or those on
immunosuppressive drugs, have higher rates of growth and
rupture [6, 51]. The prognosis of these patients depends on
the prompt recognition and early aggressive treatment. Both
endovascular and surgical techniques are safe and effective
options that have been shown to increase survival when
compared to conservative management alone [4].
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